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Abstract
Introduction and hypothesis Urethral injection therapy (UIT)
has been performed since the early 20th century and a variety
of agents have been launched. In 2006, polyacrylamide hy-
drogel (PAGH) was introduced and is now widely used as an
agent. The objective was to evaluate the efficacy of PAGH
based on a national population over a 5-year period (2007–
2011) and the influence of patient-related factors, surgeon
experience, and department volume.
Methods A retrospective cohort study was carried out based
on data from the Danish Urogynaecological Database
(DugaBase).
Results A total of 731 women were registered in the
DugaBase. Cure was achieved in 75 out of 252 women
(29.8%) and no leakage at all in 23 out of 252 (9.1%) at the
3-month follow-up. The mean total International Consultation
on Incontinence Questionnaire-Short Form (ICIQ-SF) score
decreased from 16 (SD 3.8) to 10.6 (SD 6.2; p < 0.001). UIT
was performed at 16 departments, of which four high-volume
departments performed 547 out of 814 UITs (67.2%). Women
with severe UI had a decreased chance of cure (all ICIQ-SF
scores), as did women on antimuscarinic drugs (adjusted OR
0.14; 95%, CI 0.04–0.41 Bfrequency^) and (adjusted OR 0.33;
95%, CI 0.13–0.82, Bamount^). Women treated by a high-
volume surgeon had a higher chance of cure (OR 4.51; 95%
CI, 1.21–16.82, Bfrequency^) and a lower risk of 30-day hos-
pital contacts (OR 0.27; 95% CI 0.09–0.76).
Conclusion The study represented a cure for UIT among
women in an everyday life setting. A surgeon learning curve
for UITwas indicated, as was assigning interventions to fewer
hands to improve the surgical training value and consequently
the cure rate for women with UIT.
Keywords Urethral injection therapy . Patient-related
outcomemeasures . Surgeon volume . Department volume .
National population
Introduction
Urethral injection therapy (UIT) has been performed since the
early 20th century and a variety of agents have been launched,
but many were subsequently withdrawn from the market ow-
ing to product-specific side effects [1]. Currently, UIT remains
an attractive alternative to synthetic midurethral slings (MUS)
for the treatment of female urinary incontinence (UI) because
of its minimally invasive nature and its few and mild side
effects [2].
Polyacrylamide hydrogel (PAGH), introduced in Europe as
a bulking agent in 2006, is now widely used [3]. The current
knowledge of the efficacy and safety of UIT using PAGH is
based on 10 studies with a follow-up of 1–3 years [4–13], 4 of
which are major studies [4, 8, 11, 12]. However, no national
population-based PAGH studies have been conducted and
there is a lack of studies generally, which reflects the daily
clinical practice [14]. Furthermore, patient characteristics
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associated with a decreased chance of cure among women
injected with PAGH are not well-understood [14].
A few studies have indicated that there is a learning curve
for surgeons in mastering the technique [4, 15, 16]. Two stud-
ies have up to now shown that both surgeon and department
volume have an influence on subjective outcomes in UIT [4,
15], but no major studies have assessed these aspects.
The Danish Urogynaecological Database (DugaBase) was
established in 2006 to monitor the quality of urogynaecological
surgery [17]. This national clinical database provides a unique
opportunity to retrieve information on women with UIT, as a
large population-based sample size representing several years
can be obtained.
The main purpose of the present study was to evaluate the
effect of UITon patient-reported outcomemeasures (PROMs)
and the rate of 30-day hospital contacts based on a national
background population over a 5-year period (2007–2011).
Furthermore, we examined the influence of patient-related
factors, surgeon experience, and department volume.
Materials and methods
Data sources
Data were retrieved from three Danish registers: DugaBase,
the Danish National Patient Registry, and the Register of
Medicinal Product Statistics.
All Danish residents have a unique personal identification
number that incorporates date of birth and gender and is used
for registering each individual’s contact (for purposes of con-
sultation or treatment) with the national healthcare system,
thus enabling linkage among all registries.
The DugaBase was established as a clinical database in
2006 and serves both clinical and scientific purposes
[17–19]. It comprises women residing in Denmark who at
the age of 18 or over undergo surgical procedures for UI or
pelvic organ prolapse (POP) according to the NOMESCO
procedure codes [20].
Since its establishment, pre- and postoperative question-
naires have been collected systematically [17]. These include
the International Consultation on Incontinence Questionnaire-
Short Form (ICIQ-SF), which has been translated into Danish,
but not validated, and the Patient’s Global Impression of
Improvement (PGI-I score), which was added in 2013 [18].
The database completeness of the DugaBase has increased
from 33% in 2007 to 91% in 2011 using the Danish National
Patient Registry as reference, whereas the data completeness
constantly during this period has been lower [19]. This is
mainly because follow-up after a UI procedure is not standard-
ized: some departments routinely follow up all patients,
whereas others only follow up on patients with complications.
The validity of 11 main variables has been examined and
we found 90–100% agreement when comparing information
from the database with medical records [17]. The standard for
surgical quality is set by the DugaBase steering committee
[21].
The Danish National Patient Registry was established in
1977 and provides information on diagnoses, minor proce-
dures, and surgery undergone by inpatients, outpatients and
emergency room visits in Danish hospitals [22]. Studies of
procedure codes registered in the Danish National Patient
Registry have shown a high validity [23].
It is mandatory under Danish law for all Danish hospital
departments and private hospitals to report data to the
DugaBase and the Danish National Patient Registry [22].
Furthermore, the hospitals are only reimbursed if they report
to the Danish National Patient Registry [22].
The Register of Medicinal Product Statistics was
established in 1993, and retrieves information from Danish
pharmacies on medicinal products [24].
Study population and settings
The Danish healthcare system is financed by taxes and pro-
vides care free of charge for all residents [22]. The study
population included women aged 18 years or older residing
in Denmark, who underwent first-time UIT using PAGH
from 2007 through 2011, as registered in the DugaBase. To
identify an instance of UIT in 2007 as being likely to be a
woman’s first-time UIT, we included 2006 as a lag year.
Only women who had completed the questionnaires pre-
and postoperatively were included in the main analyses
(Fig. 1). The guidelines for Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) were
adhered to [25].
In 2003, PAGH (®Bulkamid) was introduced into
Denmark, and by 2006, it had virtually replaced the previous
PAGH agent (®Aquamid) [3]. In the present study, the agent
predominantly used was PAGH (®Bulkamid), as less than
1.2% of cases (10 out of 814) involved other agents. In
Denmark, UIT in women is performed transurethrally by a
gynecologist using a urethroscope and normally three deposits
are placed between the bladder neck and mid-urethra. The
procedure is most often performed in an outpatient setting
[4]. No formal training in UIT currently exists in Denmark.
Routine, planned follow-up for the surgical treatment of UI is
normally 3 months postoperatively.
Potential predictors
Potential variables associated with the outcome of UIT were
patient-related factors, surgeon, and department volume.
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Patient-related factors
Patient-related factors included a medical history, as registered
in the DugaBase (age, body mass index [BMI], American
Society of Anesthesiologists [ASA] classification, previous
surgery (hysterectomy, UI surgery, POP), and severity of UI
preoperatively according to the ICIQ-SF score.
Information on the preoperative use of medication related
to UI was retrieved from The Register of Medicinal Product
Statistics (diuretics [ATC C03], antimuscarinic drugs [ATC
G04BD], estrogens [ATC G03C], and a group of less fre-
quently used drugs [desmopressin ATC H01BA02, imipra-
mine ATC N06AA02, and duloxetine ATC N06AX21]).
Surgeon volume
Surgeon volume, as registered in the DugaBase for each in-
stance of UIT, was categorized into three groups of surgeon
volume (number of UITs performed over their surgical ca-
reer): low (≤25), medium (26–75), and high volume (>75).
Department volume
Department volume was defined as in a previous study, high
(≥15 UITs per year) and low (<15 per year) [4]. The Danish
National Patient Registry was used to verify that the classifi-
cation of department volume was based on the actual annual
number of UITs. A total of 814 out of 1,346 UITs were actu-
ally registered in the DugaBase. Sixteen of the 22 departments
involved were registered in the DugaBase. The remaining 6
departments contributed 61 of the 1,346 UITs (4.5%). All 4
high-volume departments were registered both in the
DugaBase and the Danish National Patient Registry.
Outcome measures
The primary outcomes were based on the ICIQ-SF completed
at the 3-month follow-up after the primary UIT, and a second-
ary outcome was 30-day hospital contact.
The ICIQ-SF consists of three questions (frequency of UI,
amount of leakage, and impact of UI on daily life) and results
in a total score based on these questions (total ICIQ-SF).
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Within each of the three questions, Bcure^ was based on a
dichotomization as reported in accordance with globally ac-
cepted criteria reported previously (see Appendix, Fig. 3)
[4–8, 12, 21]. The steering committee of the DugaBase has
defined cure (a successful outcome) as leakage once a week or
less, often or never, and we focused in particular on this out-
come [21] and on Bno leakage at all^ on the frequency score,
defined as answering Bnever^ regarding leakage of urine [5].
BChange^was evaluated as the difference in the total ICIQ-SF
score, pre- and postoperatively.
All relevant instances of contact with a Department of
Obstetrics and Gynecology by women with a diagnosis classi-
fied according to the International Classification of Diseases,
tenth edition (ICD 10) [26] within 30 days of initial UIT, were
identified (referred to hereinafter as B30-day hospital contact^).
Statistical analysis
First-time UIT was the analytical unit. Descriptive statistics
were used to evaluate baseline characteristics and outcomes.
To evaluate baseline characteristics between patients treated
by a low, medium or high surgeon volume, we used the Chi-
squared test for trend (categorical variables) and one-way
analysis of variance (ANOVA; continuous variables), and
for department volume the Chi-squared test (categorical vari-
ables) and Student’s t test (continuous variables). Any change
from baseline in the ICIQ-SF scores was analyzed using the
Wilcoxon signed-rank test.
At logistic regression, the cure demonstrated in the ICIQ-SF
score postoperatively was dichotomized for all three question-
naires and adjusted according to the preoperative ICIQ-SF
score (Bseverity^). We analyzed the impact of patient-related
factors believed to be clinically relevant and the influence of
surgeon and department volume on cure by means of uni- and
multivariate logistic regression. Hosmer–Lemeshow goodness-
of-fit test was calculated to assess the fit of the models.
In the sensitivity analysis, we compared potential predictors
before surgery between women who had filled in both ques-
tionnaires pre- and postoperatively on the one hand and wom-
en who had not completed the questionnaires (pre- and/or post-
operatively) on the other. A p value < 0.05 was considered
statistically significant. Data analysis was performed using
STATA version 14.0 (StataCorp, College Station, TX, USA).
Results
Baseline characteristics
Between 1 January 2007 and 31December 2011, a total of 731
women who underwent UIT for the first time were registered
in the DugaBase. The mean age was 64, the mean BMI 26.7,
and 56.5% had mixed UI (MUI) and 31% had pure stress UI
(Table 1). Patient characteristics related to surgeon and depart-
ment volume are reported separately (see Appendix, Table 4).
Among the 252 women who had pre- and postoperatively
answered both questionnaires, 75 (29.8%) were cured and 23
(9.1%) had achieved no leakage at all by the 3-month follow-
up (Fig. 2).
For women with pure SUI, 40 out of 80 (50%) were cured,
for MUI 60 out of 141 (43%), and for UUI, 4 out of 19 (21%;
p < 0.07). There was a statistically significant improvement for
all three ICIQ-SF scores (Table 2). The mean total ICIQ-SF
score was 16.0 (SD 3.8) and after injection 10.6 (SD 6.2;
p < 0.001).
Urethral injection therapy was performed in 16 depart-
ments, of which 4 high volume departments performed 547
out of 814 UITs (67.2%). More UITs were performed by high-
volume surgeons in high-volume departments (368 out of 472
[75.9%]) compared with low-volume departments (117 out of
282 [24.1%] p < 0.001).
Table 1 Patient characteristics for women in Denmark with first-time
urethral injection therapy, 2007–2011
Variables Allb
Age, years, mean (SD) 64.0 (13.9)
BMI, mean (SD) 26.7 (5.3) c
Type of UI
Stress 152/490 (31.0)
Urgency 35/490 (7.1)
Mixed 277/490 (56.5)
Not specified 26/490 (5.3)
Smoking 100/505 (19.8)
Alcohol units per week, mean (SD) 2.8 (4.4) d
ASA
1–2 394/458(86.0)
3–5 64/458 (14.0)
Parity, mean (SD) 2.3 (1.2)e
Previous surgery
Hysterectomy 161/505 (31.8)
UI surgery 89/504 (17.7)
POP surgery 91/500 (18.2)
Use of preoperative medication
Estrogen 422/672 (62.8)
Antimuscarinic drugs 175/672 (26.0)
Diuretics 278/672 (41.3)
Other drugsa 36/672 (5.4)
BMI body mass index, ASA American Society of Anesthesiologists, UI
urinary incontinence POP pelvic organ prolapse
a Other drugs: desmopressin, imipramine or duloxetine
b n = 731, unless stated otherwise
c n = 528
d n = 420
e n = 564
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Patient-related factors
Among patient characteristics, the preoperative severity of UI sig-
nificantly decreased the likelihood of cure in all ICIQ-SF scores
(data not shown). Similarly, women on antimuscarinic drugs pre-
operatively had a significantly lower chance of cure according to
the frequency score (adjusted OR 0.14; 95%, CI 0.04–0.41) and
the amount score (adjustedOR 0.33; 95%, CI 0.13–0.82; Table 3).
There was no influence of SUI, UUI or MUI on cure.
Surgeon volume
Women treated by a high-volume surgeon had an increased
chance of cure according to the frequency score compared
with women treated by a low-volume surgeon (adjusted OR
4.51; 95% CI, 1.21–16.82) and a lower risk of hospital con-
tacts (adjusted OR 0.35; 95% CI, 0.16–0.79).
Department volume
The risk of 30-day hospital contact was lower for women
treated in a high-volume department (adjusted OR 0.27;
95% CI 0.09–0.76).
Sensitivity analyses
At baseline, only a few differences in potential predictors be-
tween women who answered both total ICIQ-SF pre- and
postoperatively and women who did not: BMI (26.4 vs 28.1,
p = 0.02), ASA 1–2 (86.9% vs 74.5%, p = 0.03), previous UI
surgery (16.5% vs 32.2%, p = 0.03), previous POP surgery
(15.6 vs 32.3%, p = 0.02), department volume (low 34.5% vs
46.1; high 65.5% vs 53.9%, p = 0.02) and surgeon volume
(low 18.2% vs 12.4%, medium 23.8% vs 15.7%; high
58.6% vs 71.9%, p = 0.03).
There were no differences in potential predictors between
women who had completed both questionnaires and women
who had only completed the questionnaire, either pre- or post-
operatively (data not shown). There were no differences in
severity of UI pre- or postoperatively, with regard to comple-
tion of all questionnaires (data not shown).
Discussion
This national population-based cohort study on transurethral
PAGH injection among 731 women, from 2007 through 2011,
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Fig. 2 Frequency, before and
after treatment—based on women
who had completed
questionnaires both pre- and
postoperatively
Table 2 Frequency, amount,
impact, and total score before and
after treatment, evaluated
according to the International
Consultation on Incontinence
Questionnaire (ICIQ-SF)—based
on women who had completed
questionnaires pre- and
postoperatively
ICIQ-SF Before (mean ± SD) After (± mean SD) Change (± mean SD) p value*
Frequency a 3.82 (1.02) 2.68 (1.54) 1.14 (1.49) 0.001
Amount b 4.00 (1.62) 2.91 (1.76) 1.08 (1.96) 0.001
Impact c 8.10 (2.26) 4.83 (3.58) 3.27 (3.30) 0.001
Total score d 16.05 (3.80) 10.58 (6.17) 5.47 (5.66) 0.001
*Wilcoxon sign-ranked test
a n =252
b n = 248
c n = 237
d n = 224
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demonstrated that 29% of thewomenwere cured and 9%had no
leakage at all at the 3-month follow-up. The mean total ICIQ-SF
score improved statistically significantly from 16 to 10.6.
Comparison with other studies of PAGH is hampered by the
usage of different PROMs, definitions of cure, sample sizes,
and follow-up periods [10, 18, 27]. The short follow-up period
of the present study differed from the ten PAGH studies that had
follow-up periods of from 1 to 3 years [4–8, 12, 13]. Moreover,
the majority of the studies reported results representing both
one or more UITs [14], as opposed to our results, which exclu-
sively represented women with first-time UIT [8].
The efficacy of PAGH in the present study may appear to
be at the lower end of the spectrum compared with the litera-
ture [4, 6–13]. However, our results represented women who
underwent UIT in an everyday life setting and surgeons with
differing experience, as opposed to prospective studies
financed by industry in which patients were Bselected^ [4, 7,
8, 11] and in which surgeons who conducted the studies were
more likely experienced surgeons from high-volume depart-
ments [4, 8].
Nevertheless, studies based exclusively on women with
severe UI or previous surgical treatment for UI reported equiv-
alent [5] or better results compared with ours [6, 12, 13]. The
women in these studies may have benefitted frommore repeat
UITs. However, only one study reported cure after the second
UIT and the chance of cure was lower than after the first UIT
[8].
Finally, definitions of both cure and no leakage at all are
fairly strict outcome measures. Synthetic MUS and
colposuspension, which are documented to be more effective
[28], only demonstrate no leakage at all achieved in 40% and
30% of the patients at the long-term follow-up [29].
Table 3 Uni- and multivariate analyses of potential predictors for cure according to the ICIQ-SF (frequency, amount, and impact)
Variables Frequency Amount Impact
Univariate
analysis
Multivariate
analysis
Univariate
analysis
Multivariate
analysis
Univariate
analysis
Multivariate
analysis
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Age, years 0.98 (0.96–1.00) 0.99 (0.96–1.03) 0.98(0.96–1.00) 0.98 (0.95–1.01) 1.01 (0.98–1.03) 1.02 (0.98–1.05)
BMI, kg/m2 0.93 (0.87–0.99) 0.94 (0.86–1.01) 0.99 (0.93–1.04) 1.01 (0.93–1.08) 0.98 (0.92–1.03) 1.00 (0.94–1.08)
Type of UI
Stress Reference – Reference – Reference –
Urgency 0.42 (0.12–1.46) 0.65 (0.22–1.93) 1.15 (0.37–3.55)
Mixed 1.19 (0.63–2.24) 0.96 (0.52–1.78) 1.76 (0.88–3.48)
Not specified 2.82 (0.70–11.22) 0.55 (0.14–2.12) 0.77 (0.19–3.12)
ASA
1–2 Reference Reference Reference Reference Reference Reference
3–5 0.53 (0.33–0.84) 0.67 (0.34–1.3) 0.67 (0.43–1.05) 0.81 (0.43–1.51) 0.80 (0.50–1.28) 0.80 (0.42–1.51)
Parity 1.31 (1.03–1.66) 1.26 (0.97–1.65) 1.34 (1.07–1.69) 1.09 (0.84–1.4) 1.11 (0.87–1.42) 1.13 (0.87–1.47)–
Previous surgery
Hysterectomy 1.18 (0.65–2.12) 1.12 (0.46–2.69) 1.72 (0.92–3.21) 1.44 (0.59–3.48) 1.09 (0.57–2.07) 0.64 (0.27–1.54)
UI surgery 1.21 (0.59–2.46) 1.82 (0.56–5.93) 0.99 (0.45–2.14) 0.62 (0.18–2.09) 0.68 (0.30–1.51) 1.18 (0.37–3.74)
POP surgery 1.07 (0.51–2.26) 0.39 (0.10–1.54) 1.47 (0.65–3.34) 5.62 (1.25–25.32) 0.84 (0.34–2.04) 0.80 (0.21–2.96)
Preoperative medication
Estrogen 0.62 (0.34–1.14) 0.62 (0.25–1.57) 0.55 (0.29–1.00) 0.56 (0.22–1.40) 0.78 (0.41–1.49) 1.12 (0.46–2.7)
Antimuscarinic
drugs
0.34 (0.16–0.71) 0.14 (0.04–0.41) 0.42 (0.21–0.83) 0.33 (0.13–0.82) 0.92 (0.45–1.86) 0.87 (0.35–2.14)
Diuretics 0.81 (0.45–1.46) 0.99 (0.4–2.43) 1.29 (0.72–2.3) 0.75 (0.32–1.78) 1.24 (0.67–2.31) 0.88 (0.37–2.10)
Surgeon volume
Low Reference Reference Reference Reference Reference Reference
Medium 2.25 (0.86–5.88) 1.95 (0.57–6.58) 0.44 (0.17–1.1) 0.39 (0.15–1.04) 1.3 (0.49–3.46) 1.03 (0.3–3.58)
High 2.59 (1.11–5.99) 4.51 (1.21–16.82) 0.86 (0.39–1.9) 0.64 (0.17–2.25) 1.42 (0.61–3.33) 1.83 (0.48–6.94)
Department volume
Low Reference Reference Reference Reference Reference Reference
High 0.84 (0.47–1.50) 0.96 (0.26–3.58) 1.01 (0.57–1.78) 1.5 (0.42–5.29) 0.82 (0.44–1.50) 0.72 (0.19–2.7)
Cure was dichotomized (see Appendix, Fig. 3) and throughout all analyses, adjusted according to the preoperative ICIQ-SF score (Bseverity^)
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Even though the UIT cure rate may seem low, it still re-
mains a viable option as it is less invasive and has fewer and
milder side effects compared with synthetic MUS [14].
Similarly, the present study identified only a few patient
characteristics that were predictors of a lower chance of cure.
The severity of UI preoperatively was consistently and inde-
pendently associated with lower chance of cure in all ICIQ-SF
scores. There was no obvious influence of MUI and UUI on
cure, although the absolute likelihood of cure for women with
UUI was somewhat lower. Previous studies found a borderline
poorer outcome for women with MUI injected with PAGH [4,
8, 10].Womenwho used an antimuscarinic drug preoperative-
ly had a decreased likelihood of cure and this may indicate that
womenwith the most severe forms ofMUI and UUImay have
a decreased chance of cure. It seems paradoxical that the pre-
dictors for a lower chance of cure were found among women
who most often have UIT, i.e., women with severe UI or
severe MUI/UUI who are not candidates for synthetic MUS.
This emphasizes the need for proper patient counselling to
provide womenwith realistic expectations regarding outcome.
Women treated by a high -volume surgeon (>75 UITs) had
significantly better outcomes on the frequency score and a sig-
nificantly lower risk of 30-day hospital contact. Only two stud-
ies to date have pointed to a learning curve for UIT [4, 15] and
the present study likewise only indicated this. Women treated at
high-volume departments had a significantly lower risk of 30-
day hospital contact, which corresponds to a previous multicen-
ter study, which showed better results for departments that
injected >15 UITs per year [4]. The influence of department
volume in the present study probably reflects that significantly
more surgeries were performed by high-volume surgeons in
high-volume departments compared with low-volume depart-
ments. The majority of departments (12 out of 16) rarely per-
formed UIT. As the annual number of UITs has decreased to
200 UITs during recent years in Denmark [30], a surgeon vol-
ume of >75 UITs will be difficult to achieve in the future.
The study has several strengths. We reported outcomes
based on a national population of women consecutively reg-
istered in the DugaBase. This represented everyday life, un-
like previous studies, which were either financed by industry
with several exclusion criteria [5, 6, 9, 10] or involved women
with severe UI [6] and previous surgical treatment [4, 7, 8, 11].
To the best of our knowledge, this is the largest study of UIT
mainly using PAGH. We reported on issues not addressed
previously including several clinical confounders. As out-
come data were collected independently of the surgeon, the
risk of investigator bias was minimized.
There were also limitations to the study, as we were only
able to examine PROMs at short-term follow-up.
Furthermore, our study indicated a learning curve for UIT.
Future studies including more PROMs (e.g., the PGI-I score)
will perhaps support evidence for a learning curve within UIT.
Studies that explore aspects of this field are also needed, e.g.,
the threshold for acquiring the skill and which areas should be
practiced.
Furthermore, we had no information on objective outcome
measures and no reliable registration of surgical complica-
tions. There is at present focus on improving the database
completeness for objective outcome measures, which will
make future studies within this field possible.
Because of the low database completeness of the
DugaBase at the beginning of our study period [21], we can-
not exclude some selection bias, as not all low-volume depart-
ments were included in the study. However, as all four high-
volume departments were registered in the DugaBase and per-
formed the majority of the UITs, the lack of a few low-volume
departments seems to be of minor importance, as their UIT
contribution was small. Last but not least, there was a possible
selection bias related to the patient characteristics, as women
who had fulfilled both questionnaires were healthier (lower
BMI, lower ASA score, and with less POP/UI surgery behind
them) and more often from high-volume departments, com-
pared with women who had not completed the questionnaires.
Conclusion
This national population-based cohort study represented wom-
en with a first-time injection at the 3-month follow-up in an
everyday life setting. The results may seem to be at the lower
end of the spectrum in comparison to the literature. However,
UIT cure should be considered in the light of the fact that it is
often performed in women who are not clinically suitable can-
didates for having or being willing to have a synthetic MUS.
The severity of UI preoperatively was a strong predictor of a
lower chance of cure and, similarly, the use of antimuscarinic
drugs preoperatively indicated a poorer outcome for women
with severe MUI and UUI. A learning curve for UIT was
indicated, as was the recommendation that the treatment
should be restricted to fewer hands to improve surgeon training
and consequently the cure rate for women with UIT.
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Fig. 3 The International
Consultation on Incontinence
Questionnaire Short Form (ICIQ-
SF)
Table 4 Patient characteristics related to surgeon and department volume in Denmark, 2007–2011
Variables Surgeon volumea Department volumeb p value
0–25 26–75 >75 p value 0–15 >15
Age, years, mean (SD) 66.5 (13.1) c 64.8 (13.9) d 63.5 (14.2) e 0.07 63.0 (15.0) f 65.4 (13.2) g 0.02
BMI, mean (SD) 28.2 (6.4) h 27.2 (5.6) i 26.3 (4.9) j 0.002 28 (6.4) k 26.2 (4.7) l 0.001
ICIQ-SF, total preoperatively (SD) 15.2 (4.5)m 16 (3.8)n 16 (3.7)o 0.58 15.9 (3.8)p 15.9 (3.9)q 0.93
Type of UI
Stress 33/85 (38.8) 24/101 (23.7) 103/323 (31.9) 0.3 54/170 (31.8) 115/375 (30.7) 0.52
Urgency 5/85 (5.8) 9/101 (8.9) 17/323 (5.2) 9/170 (5.3) 29//375 (7.7)
Mixed 43/85 (50.6) 64/ 101 (63.4) 183/ 323 (56.7) 99/170 (58.2) 205/375 (54.7)
Not specified 4/85 (4.7) 4/ 101 (3.9) 20/323 (6.2) 8/170 (4.7) 26/375 (6.9)
Smoking 18/74 (24.3) 17/91 (18.7) 61/317 (19.2) 0.58 36/156 (23.1) 64/349 (18.3) 0.22
Alcohol units per week, mean(SD) 2.3 (4.0) r 2.8 (4.5) s 2.7 (4.3) t 0.78 2.7 (4.3) u 2.8 (4.4) v 0.71
ASA
1–2 64/ 86 (74.4) 82/98 (83.7) 272/301 (90.3) 0.001 138/172 (80.2) 289/324 (89.2) 0.006
3-5 22/86 (25.6) 16/98 (16.3) 29/301 (9.6) 34/172 (19.8) 35/324 (10.8)
Parity, mean (SD) 2.3 (1.2) w 2.2 (1.3) x 2.3 (1.2) y 0.31 2.1 (1.2) z 2.3 (1.2) † 0.03
Previous surgery
Hysterectomy 34/91 (37.4) 29/107 (27.1) 104/330 (31.5) 0.30 57/179 (31.8) 123/380 (32.4) 0.90
UI surgery 17/92 (18.5) 19/108 (17.6) 60/326 (18.4) 0.98 28/180 (15.6) 73/378 (19.3) 0.28
POP surgery 15/90 (16.7) 20/105 (19.0) 64/326 (19.6) 0.82 34/177 (19.2) 72/377 (19.1) 0.98
Use of preoperative medication
Estrogen 84/119 (70.6) 92/133 (69.2) 268/439 (61) 0.02 159/258 (61.6) 324/491 (65.9) 0.23
Antimuscarinic drugs 84/119 (70.6) 38/133 (28.5) 109/439 (24.8) 0.46 63/258 (24.4) 125/491 (25.5) 0.76
Diuretics 62/119 (52.1) 56/133 (42.1) 174/439 (39.6) 0.02 114/258 (44.2) 204/491 (41.6) 0.49
Other drugs 4/119 (3.4) 5/133 (3.8) 27/439 (6.2) 0.25 9/258 (3.5) 32/491 (6.5) 0.08
a Number of urethral injections performed by the surgeon or annually
b Number of urethral injections performed annually by the department
Age: c n = 128; d n = 141; e n = 485; f n = 283; g n = 531
BMI: h n = 94; i n = 107; j n = 355; k n = 186; l n = 400
ICIQ-SF, total preoperatively (SD): m n = 79; n n = 97; o n = 303; p n = 159; q n = 370
Alcohol units per week: r n = 65; s n = 93; t n = 289; u n = 148; v n = 320
Parity: w n = 91; x n = 106; y n = 333; z n = 184; † n = 580
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